These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1819473)

  • 1. Determination of protein-bound urinary gamma-carboxyglutamic acid in calcium nephrolithiasis.
    Colette C; Benmbarek A; Boniface H; Astre C; Pares-Herbute N; Monnier L; Guitter J
    Clin Chim Acta; 1991 Dec; 204(1-3):43-50. PubMed ID: 1819473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium oxalate crystallisation kinetics and the effects of calcium and gamma-carboxyglutamic acid.
    Nishio S; Kavanagh JP; Faragher EB; Garside J; Blacklock NJ
    Br J Urol; 1990 Oct; 66(4):351-6. PubMed ID: 2224428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid assay for gamma-carboxyglutamic acid in urine and bone by precolumn derivatization and reversed-phase liquid chromatography.
    Haroon Y
    Anal Biochem; 1984 Aug; 140(2):343-8. PubMed ID: 6486421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis.
    Nakagawa Y; Abram V; Parks JH; Lau HS; Kawooya JK; Coe FL
    J Clin Invest; 1985 Oct; 76(4):1455-62. PubMed ID: 4056037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulatory effect of the 23-kD calcium oxalate monohydrate binding protein on calcium oxalate stone formation during oxalate stress.
    Asokan D; Kalaiselvi P; Varalakshmi P
    Nephron Physiol; 2004; 97(1):p23-30. PubMed ID: 15153748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid.
    Nakagawa Y; Ahmed M; Hall SL; Deganello S; Coe FL
    J Clin Invest; 1987 Jun; 79(6):1782-7. PubMed ID: 3584470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium oxalate monohydrate binding protein: a diagnostic biomarker for calcium oxalate kidney stone formers.
    Asokan D; Kalaiselvi P; Muhammed Farooq S; Varalakshmi P
    Urol Res; 2004 Oct; 32(5):357-61. PubMed ID: 15365653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis.
    Coe FL; Nakagawa Y; Asplin J; Parks JH
    Miner Electrolyte Metab; 1994; 20(6):378-84. PubMed ID: 7783700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A study on urinary free gamma-carboxyglutamic acid in patients with idiopathic urinary calcium stone].
    Motomiya Y; Sasaki K; Maruyama Y; Arai K; Ozono S; Hirao Y; Okajima E; Uji Y; Okabe H
    Nihon Hinyokika Gakkai Zasshi; 1992 Dec; 83(12):2085-9. PubMed ID: 1474719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristic clinical and biochemical profile of recurrent calcium-oxalate nephrolithiasis in patients with metabolic syndrome.
    Rendina D; De Filippo G; Zampa G; Muscariello R; Mossetti G; Strazzullo P
    Nephrol Dial Transplant; 2011 Jul; 26(7):2256-63. PubMed ID: 21051502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function.
    Jaggi M; Nakagawa Y; Zipperle L; Hess B
    Urol Res; 2007 Apr; 35(2):55-62. PubMed ID: 17345077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory activity of whole urine: a comparison of urines from stone formers and healthy subjects.
    Ryall RL; Hibberd CM; Mazzachi BC; Marshall VR
    Clin Chim Acta; 1986 Jan; 154(1):59-67. PubMed ID: 3943225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion.
    Nakagawa Y
    Keio J Med; 1997 Mar; 46(1):1-9. PubMed ID: 9095576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein inhibitors of crystal growth.
    Kaiser ET; Bock SC
    J Urol; 1989 Mar; 141(3 Pt 2):750-2. PubMed ID: 2645434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperoxaluria in idiopathic calcium nephrolithiasis--what are the limits?
    Osther PJ
    Scand J Urol Nephrol; 1999 Dec; 33(6):368-71. PubMed ID: 10636575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of urinary macromolecules on aggregation of calcium oxalate in recurrent calcium stone formers and healthy.
    Ebisuno S; Kohjimoto Y; Yoshida T; Ohkawa T
    Urol Res; 1993; 21(4):265-8. PubMed ID: 8212414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium-binding proteins and renal lithiasis.
    Resnick MI; Gammon CW; Sorrell MB; Boyce WH
    Surgery; 1980 Aug; 88(2):239-43. PubMed ID: 7394705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An improved method for the determination of gamma-carboxyglutamic acid in proteins, bone, and urine.
    Kuwada M; Katayama K
    Anal Biochem; 1983 May; 131(1):173-9. PubMed ID: 6614448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced inhibitory activity of uronic-acid-rich protein in urine of stone formers.
    Atmani F; Lacour B; Jungers P; Drüeke T; Daudon M
    Urol Res; 1994; 22(4):257-60. PubMed ID: 7871640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.